HARMONY Trial Introduces Adaptive PARP Inhibitor Strategy for Metastatic Prostate Cancer with Focus on Underrepresented Populations
核心洞察
The phase 2 HARMONY trial evaluates an adaptive treatment approach using niraparib plus abiraterone in treatment-naive metastatic hormone-sensitive prostate cancer (搜索) patients with HRR alterations.
The study allows treatment escalation or de-escalation based on PSA (搜索) response at 24 weeks, offering patients choice between continuing niraparib-based therapy or switching to docetaxel-based regimens.
HARMONY specifically prioritizes enrollment of non-Hispanic Black and Hispanic/Latino patients, who historically represent less than 15% of participants in pivotal prostate cancer (搜索) trials.
The phase 2 HARMONY trial (NCT06392841) represents a novel approach to PARP (搜索) inhibitor therapy in metastatic hormone-sensitive prostate cancer (搜索) (mHSPC), incorporating an adaptive design that allows treatment decisions based on prostate-specific antigen (PSA (搜索)) response dynamics while prioritizing enrollment of historically underrepresented patient populations.
Adaptive Treatment Strategy Based on PSA Response
The HARMONY trial evaluates niraparib (Zejula) plus abiraterone acetate (Zytiga) and prednisone in patients with treatment-naive mHSPC harboring deleterious homologous recombination repair (搜索) (HRR) alterations. According to Dr. Qian (Janie) Qin from UT Southwestern Medical Center (搜索), "The HARMONY trial is more of an adaptive trial that allows patient to have a choice [of treatment] based on their PSA (搜索) response."
All patients initially receive androgen deprivation therapy (ADT) in combination with niraparib during a 24-week induction phase. PSA (搜索) kinetics during this period guide subsequent treatment decisions, with the trial structure allowing treatment to be tailored according to early biomarkers of response.
For patients who do not achieve optimal PSA (搜索) level decline—defined as PSA levels remaining above 4 ng/mL without radiographic or clinical progression—treatment intensification is permitted. These patients may either continue the triplet regimen of ADT plus abiraterone and niraparib or transition to an alternative triplet strategy by discontinuing niraparib and adding docetaxel to ADT and abiraterone.
Treatment De-escalation Options
Patients achieving PSA (搜索) level reduction to 4 ng/mL or lower at the 24-week mark are eligible to continue receiving the niraparib-based triplet regimen for a total of one year. At the 12-month time point, treatment is further stratified based on PSA response.
Patients achieving deep PSA (搜索) level suppression to less than 0.2 ng/mL may choose either to discontinue therapy—a de-escalation strategy—or maintain treatment. Patients with PSA levels of at least 0.2 ng/mL will be advised to continue receiving the niraparib-based triplet until disease progression or unacceptable toxicity, for a maximum duration of two years.
Addressing Health Disparities in Clinical Research
A distinguishing feature of the HARMONY trial is its intentional prioritization of enrollment among historically underrepresented populations in prostate cancer (搜索) research. Dr. Qin noted that prior pivotal phase 3 trials leading to current standard-of-care therapies for prostate cancer patients included disproportionately low numbers of racial and ethnic minority patients.
"The African American patient population usually represents less than 3% to 5% of the enrolled patients; Hispanic/Latino patients usually [represent] less than 10% to 15% [of the total population on clinical trials]," Dr. Qin stated. HARMONY is specifically designed to increase participation of non-Hispanic Black and Hispanic/Latino patients.
The goal is to elucidate potential differences in HRR alterations, therapeutic response, and toxicity profiles between these populations, thereby generating more inclusive and clinically relevant data to inform precision medicine approaches in prostate cancer (搜索) care.
Clinical Context and Molecular Testing
The investigational therapeutic backbone under evaluation in HARMONY is composed of the same agents evaluated in the investigational arm of the phase 3 AMPLITUDE trial (NCT04497844) in patients with metastatic castration-sensitive prostate cancer (搜索). Dr. Qin emphasized the importance of early molecular testing, stating, "Getting somatic testing and hereditary testing in the hormone-sensitive setting allows me to plan [ahead] for the first-line mCRPC setting, because it does take 2 to 3 weeks for those results to come back."
The adaptive design of HARMONY represents an evolution in PARP (搜索) inhibitor development, building on previous monotherapy trials including PROfound with olaparib and TRITON-3 with rucaparib, as well as combination regimens evaluated in PROpel, MAGNITUDE, and TALAPRO-2 trials in the metastatic castration-resistant prostate cancer (搜索) setting.